{
    "medicine_id": "dcbc1480ed6920099f33b9a4fa4b6530c2093725",
    "platform_id": "DB05505",
    "metadata": {
        "name": "Adult Formula 50 60 61 v v Solution",
        "composition": "60 61 v v NM 702",
        "clinical_particulars": {
            "therapeutic_indications": "Investigated for use treatment in peripheral vascular disease",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Intermittent claudication is a major symptom of arteriosclerosis obliterans It is caused by insufficient oxygen supply to exercising muscles in the lower extremities due to decreased blood flow as a result of sclerosis of peripheral arteries Patients with claudication experience significant disability owing to their exercise limitation Therapeutic options to improve exercise performance in these patients are limited NM 702 is a novel drug that inhibits phosphodiesterase as well as thromboxane A2 synthase",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}